The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex

Brain Research

Volumn 1311, Issue , 2010, Pages 28-36

  Li, Zhimin ^a   Boules, Mona ^a   Williams, Katrina ^a   Peris, Joanna ^b   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Glutamate; Glycine; Medial prefrontal cortex; Monoamine; NT69L; Schizophrenia

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; AMINO ACID; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; GLUTAMIC ACID; GLYCINE; MONOAMINE; NEUROTENSIN DERIVATIVE; NEUROTENSIN[69 LEUCINE]; NEUROTENSIN[8-13]; NORADRENALIN; PHENCYCLIDINE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; EXTRACELLULAR SPACE; HYPERACTIVITY; LOCOMOTION; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SPRAGUE DAWLEY RAT;

AMINO ACIDS; ANIMALS; ANTIPSYCHOTIC AGENTS; BIOGENIC MONOAMINES; CENTRAL NERVOUS SYSTEM AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE; EXTRACELLULAR SPACE; GLUTAMIC ACID; GLYCINE; MALE; MOTOR ACTIVITY; NEUROTENSIN; NOREPINEPHRINE; PEPTIDE FRAGMENTS; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; SEROTONIN;

ANIMALIA; RATTUS; RODENTIA;

EID: 72649096963     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.11.048     Document Type: Article

References (64)

1. Abekawa T., Ito K., and Koyama T. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 374 (2006) 177-193
2. Abekawa T., Ito K., and Koyama T. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic. Naunyn Schmiedebergs Arch. Pharmacol. 375 (2007) 261-271
3. Adams B., and Moghaddam B. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci. 18 (1998) 5545-5554
4. Amargos-Bosch M., Lopez-Gil X., Artigas F., and Adell A. Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int. J. Neuropsychopharmacol. 9 (2006) 565-573
5. Antonelli T., Fuxe K., Tomasini M.C., Mazzoni E., Agnati L.F., Tanganelli S., and Ferraro L. Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment. Prog. Neurobiol. 83 (2007) 92-109
6. Arnsten A.F. Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 174 (2004) 25-31
7. Asselin M.L., Dubuc I., Coquerel A., and Costentin J. Localization of neurotensin NTS2 receptors in rat brain, using. Neuroreport 12 (2001) 1087-1091
8. Berendse H.W., Galis-de Graaf Y., and Groenewegen H.J. Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J. Comp. Neurol. 316 (1992) 314-347
9. Bertollo D.N., Cowen M.A., and Levy A.V. Hypometabolism in olfactory cortical projection areas of male patients with schizophrenia: an initial positron emission tomography study. Psychiatry Res. 60 (1996) 113-116
10. Boules M., Cusack B., Zhao L., Fauq A., McCormick D.J., and Richelson E. A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Res. 865 (2000) 35-44
11. Boules M., Fredrickson P., and Richelson E. Bioactive analogs of neurotensin. Peptides 27 (2006) 2523-2533
12. Boules M., McMahon B., Wang R., Warrington L., Stewart J., Yerbury S., Fauq A., McCormick D., and Richelson E. Selective tolerance to the hypothermic and anticataleptic effects of a neurotensin analog that crosses the blood-brain barrier. Brain Res. 987 (2003) 39-48
13. Boules M., Warrington L., Fauq A., McCormick D., and Richelson E. A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 426 (2001) 73-76
14. Bowser M.T., and Kennedy R.T. In vivo monitoring of amine neurotransmitters using microdialysis with on-line capillary electrophoresis. Electrophoresis 22 (2001) 3668-3676
15. Breier A., Buchanan R.W., Waltrip II R.W., Listwak S., Holmes C., and Goldstein D.S. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology 10 (1994) 1-7
16. Breslin N.A., Suddath R.L., Bissette G., Nemeroff C.B., Lowrimore P., and Weinberger D.R. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Schizophr. Res. 12 (1994) 35-41
17. Carraway R., and Leeman S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 248 (1973) 6854-6861
18. Cleghorn J.M., Franco S., Szechtman B., Kaplan R.D., Szechtman H., Brown G.M., Nahmias C., and Garnett E.S. Toward a brain map of auditory hallucinations. Am. J. Psychiatry 149 (1992) 1062-1069
19. Coyle J.T., and Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174 (2004) 32-38
20. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., and Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res. 856 (2000) 48-54
21. Doherty J.D., Simonovic M., So R., and Meltzer H.Y. The effect of phencyclidine on dopamine synthesis and metabolic in rat striatum. Eur. J. Pharmacol. 65 (1980) 139-149
22. Feifel D., Reza T.L., Wustrow D.J., and Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J. Pharmacol. Exp. Ther. 288 (1999) 710-713
23. Ferraro L., Tomasini M.C., Fernandez M., Bebe B.W., O'Connor W.T., Fuxe K., Glennon J.C., Tanganelli S., and Antonelli T. Nigral neurotensin receptor regulation of nigral glutamate and nigroventral thalamic GABA transmission: a dual-probe microdialysis study in intact conscious rat brain. Neuroscience 102 (2001) 113-120
24. Fuster J.M. The Prefrontal Cortex: Anatomy, Physiology, and Neuropsychology of the Frontal Lobe. 2nd ed. (1989), Raven Press, New York
25. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., and Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-d-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry 157 (2000) 1141-1149
26. Garver D.L., Bissette G., Yao J.K., and Nemeroff C.B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry 148 (1991) 484-488
27. Goldberg T.E., Bigelow L.B., Weinberger D.R., Daniel D.G., and Kleinman J.E. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am. J. Psychiatry 148 (1991) 78-84
28. Goldman-Rakic P.S., Muly III E.C., and Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Res. Brain Res. Rev. 31 (2000) 295-301
29. Gozzi A., Herdon H., Schwarz A., Bertani S., Crestan V., Turrini G., and Bifone A. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 201 (2008) 273-284
30. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N, Nakazato M., Kumakiri C., Okada S., Hasegawa H., Imai K., Iyo M., 2003. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry 60, 572-576.
31. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., and Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry 56 (1999) 29-36
32. Heritch A.J. Evidence for reduced and dysregulated turnover of dopamine in schizophrenia. Schizophr. Bull. 16 (1990) 605-615
33. Hertel P., Mathe J.M., Nomikos G.G., Iurlo M., Mathe A.A., and Svensson T.H. Effects of d-amphetamine and phencyclidine on behavior and extracellular concentrations of neurotensin and dopamine in the ventral striatum and the medial prefrontal cortex of the rat. Behav. Brain Res. 72 (1995) 103-114
34. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
35. Jentsch J.D., Elsworth J.D., Redmond Jr. D.E., and Roth R.H. Phencyclidine increases forebrain monoamine metabolism in rats and monkeys: modulation by the isomers of HA966. J. Neurosci. 17 (1997) 1769-1775
36. Jentsch J.D., and Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 (1999) 201-225
37. Kerwin R., Patel S., and Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39 (1990) 25-32
38. Lada M.W., and Kennedy R.T. Quantitative in vivo monitoring of primary amines in rat caudate nucleus using microdialysis coupled by a flow-gated interface to capillary electrophoresis with laser-induced fluorescence detection. Anal. Chem. 68 (1996) 2790-2797
39. Liang Y., Boules M., Shaw A.M., Williams K., Fredrickson P., and Richelson E. Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain. Brain Res. 1231 (2008) 6-15
40. Marwaha J. Candidate mechanisms underlying phencyclidine-induced psychosis: an electrophysiological behavioral, and biochemical study. Biol. Psychiatry 17 (1982) 155-198
41. McGuire P.K., Shah G.M., and Murray R.M. Increased blood flow in Broca's area during auditory hallucinations in schizophrenia. Lancet 342 (1993) 703-706
42. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. Biol. Psychiatry 51 (2002) 775-787
43. Nemeroff C.B. The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. Psychoneuroendocrinology 11 (1986) 15-37
44. Ohuoha D.C., Hyde T.M., and Kleinman J.E. The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system. Psychopharmacology (Berl) 112 (1993) S5-15
45. Park S., and Holzman P.S. Schizophrenics show spatial working memory deficits. Arch. Gen. Psychiatry 49 (1992) 975-982
46. Pearlson G.D., Petty R.G., Ross C.A., and Tien A.Y. Schizophrenia: a disease of heteromodal association cortex?. Neuropsychopharmacology 14 (1996) 1-17
47. Petrie K.A., Schmidt D., Bubser M., Fadel J., Carraway R.E., and Deutch A.Y. Neurotensin activates GABAergic interneurons in the prefrontal cortex. J. Neurosci. 25 (2005) 1629-1636
48. Prus A.J., Huang M., Li Z., Dai J., and Meltzer H.Y. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Brain Res. 1184 (2007) 354-364
49. Richelson E., Boules M., and Fredrickson P. Neurotensin agonists: possible drugs for treatment of psychostimulant abuse. Life Sci. 73 (2003) 679-690
50. Sanz B., Exposito I., and Mora F. Effects of neurotensin on the release of glutamic acid in the prefrontal cortex and striatum of the rat. Neuroreport 4 (1993) 1194-1196
51. Sesack S.R., Carr D.B., Omelchenko N., and Pinto A. Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann. N. Y. Acad. Sci. 1003 (2003) 36-52
52. Sharma R.P., Janicak P.G., Bissette G., and Nemeroff C.B. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am. J. Psychiatry 154 (1997) 1019-1021
53. Shilling P.D., Richelson E., and Feifel D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav. Brain Res. 143 (2003) 7-14
54. Smith A., Watson C.J., Frantz K.J., Eppler B., Kennedy R.T., and Peris J. Differential increase in taurine levels by low-dose ethanol in the dorsal and ventral striatum revealed by microdialysis with on-line capillary electrophoresis. Alcohol Clin. Exp. Res. 28 (2004) 1028-1038
55. Snyder S.H. Phencyclidine Nature 285 (1980) 355-356
56. Steketee J.D. Neurotransmitter systems of the medial prefrontal cortex: potential role in sensitization to psychostimulants. Brain Res. Brain Res. Rev. 41 (2003) 203-228
57. Tamminga C.A., LeWitt P.A., and Chase T.N. Cholecystokinin and neurotensin gradients in human CSF. Arch. Neurol. 42 (1985) 354-355
58. Thierry A.M., Godbout R., Mantz J., and Glowinski J. Influence of the ascending monoaminergic systems on the activity of the rat prefrontal cortex. Prog. Brain Res. 85 (1990) 357-364 discussion. 364-355
59. Uhl G.R. Distribution of neurotensin and its receptor in the central nervous system. Ann. N. Y. Acad. Sci. 400 (1982) 132-149
60. Verma A., and Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16 (1996) 373-379
61. Wachi M., Okuda M., Togashi S., Fuwano S., and Miyashita O. Effects of phencyclidine administration on behavior and brain neurotensin-like immunoreactivity in rats. Brain Res. 333 (1985) 393-396
62. Wang Rui M.B., Tiner W., and Richelson E. Effects of repeated injections of the neurotensin analog NT69L on dopamine release and uptake in rat striatum in vitro. Brain Res. 1025 (2004) 21-28
63. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44 (1987) 660-669
64. Zavitsanou K., Ward P.B., and Huang X.F. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 27 (2002) 826-833